Last updated: February 15, 2026
What is the current market position of drug NDC 42291-0699?
The drug associated with NDC 42291-0699 is Rimegepant, marketed primarily under the brand Nurtec ODT. Approved by the FDA in 2019 for acute treatment of migraines and preventive therapy, Rimegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist.
The drug's market presence is characterized by strong patent protection until 2032 and initial competitive advantage due to its dual-use label (acute and preventive). Sales momentum has increased particularly following expansion of indications and pediatric approvals.
Market penetration is gaining traction in the migraine therapeutics market, which was valued at approximately USD 4 billion in 2022 and expected to grow at 8-10% CAGR over the next five years ([1]).
How does the current pricing structure compare to alternatives?
Current Wholesale Acquisition Cost (WAC)
- Average WAC for Nurtec ODT: around USD 1,150 per 30-count pack.
- Typical patient out-of-pocket cost with insurance ranges from USD 25 to USD 75 per prescription, depending on coverage.
Pricing vs. Competitors
| Drug |
Indication |
List Price (USD) |
Market Share (2022) |
Approval Status |
| Nurtec ODT |
Migraine (acute & preventive) |
1,150 |
45% |
Approved 2019 |
| Emgality (Galcanezumab) |
Migraine (preventive) |
6,950 annually |
30% |
Approved 2018 |
| Ajovy ( Fremanezumab) |
Preventive |
6,650 annually |
15% |
Approved 2017 |
| Aimovig (Erenumab) |
Preventive |
6,500 annually |
10% |
Approved 2018 |
Nurtec professionals highlight its oral delivery, shorter onset, and dual-use as competitive advantages over injectable CGRP antagonists.
Insurance and Reimbursement Dynamics
Typically, insurance reimbursement aligns with list prices; however, with increasing use, payers seek negotiated discounts. The average out-of-pocket expense for patients may remain stable due to manufacturer patient assistance programs.
What are the anticipated price projections over the next five years?
Factors influencing price trends:
- Patent expiry: Protects current pricing until approximately 2032; no significant generic competition expected before then.
- Market expansion: Increasing indication approvals for preventive use will likely sustain or increase price sensitivity.
- Manufacturing costs: Slight decrease projected due to process optimizations and competition from biosimilars or generics is unlikely given the drug’s small-molecule nature.
- Reimbursement strategies: Payers may push for discounts as competition increases; however, the dual-route therapy maintains some pricing power.
Projected Price Range 2023-2028
| Year |
Estimated WAC Range (USD) |
Notes |
| 2023 |
1,120 – 1,150 |
Stable, with minor fluctuations |
| 2024 |
1,100 – 1,140 |
Slight pressure from payer negotiations |
| 2025 |
1,090 – 1,130 |
Continued brand dominance |
| 2026 |
1,080 – 1,120 |
Possible stabilization |
| 2027 |
1,070 – 1,110 |
Marginal decreases possible |
Any significant shifts are unlikely before patent expiry unless a biosimilar enters the market.
How does regulatory and policy environment impact the market?
- The FDA's recent policies encourage expanded indications, potentially increasing market size but not necessarily affecting price.
- CMS and private insurers utilize formulary management and prior authorization, influencing net price and access, but not necessarily list price.
- Legislation targeting drug pricing transparency may impact negotiated discounts but is not expected to reduce list prices substantially prior to patent expiration.
Conclusions
The drug NDC 42291-0699 (Rimegepant/Nurtec ODT) holds a robust market position with minimal near-term price erosion risks due to patent protections, limited immediate generic competition, and ongoing market expansion. Price levels will likely remain steady, subject to payer negotiations, until at least 2032.
Key Takeaways
- Nurtec ODT's current WAC stands at approximately USD 1,150 per 30-count pack.
- Market growth driven by expanded indications is expected to sustain demand.
- Direct generic competition unlikely before patent expiry in 2032.
- Future price adjustments will primarily depend on payer negotiations and market expansion.
FAQs
1. Will generic versions of Nurtec ODT enter the market before 2032?
No. Patent protection lasts until 2032; generic entry is unlikely prior to expiry.
2. How do insurance plans affect the net price for patients?
Insurance negotiations and formularies influence copay amounts; patient assistance programs can reduce out-of-pocket costs.
3. Is significant price reduction expected after patent expiry?
Yes. Entry of generics typically results in steep price declines, often 60% or more.
4. How does Nurtec's pricing compare to injectable CGRP antagonists?
Nurtec's list price is lower, but specialty injectables often have higher overall costs, with certain insurance plans favoring injectables through negotiated rebates.
5. What impact could future indication expansions have on pricing?
Additional indications could expand market size, enabling sustained or slightly increased pricing power.
References
[1] IQVIA, "The Future of Migraine Treatment," 2022.
